S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Common stock · Exchange Nasdaq Global Select Market · Ticker ETRA · Use of proceeds to advance development of ipsoprubart and ELA822, support clinical trials, and fund research and development activities
Electra Therapeutics, Inc. is conducting an IPO with a focus on converting redeemable convertible preferred stock into common stock, implementing a reverse stock split, and detailing financial losses. The filing includes pro forma financial data assuming these conversions and a potential offering. The company remains unprofitable, with significant accumulated deficits and ongoing research and development expenses.
2026-08-28 · 0001193125-26-374259
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
2026-08-10 · 0001193125-26-342694
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
2026-06-26 · 0001193125-26-285726